image: On September 7 (16:55–17:30), he will participate in "The Future Investment Circle" panel discussion and deliver a talk titled "The Longevity Thesis: Investing in the human lifespan". On September 8 (15:50–16:05), he will take part in a Special Spotlight Fireside session titled "AI for Science: Building the Next Trillion-Dollar Innovation Economy".
Credit: Insilico Medicine
September 7–9 | Dubai
Dr. Alex Aliper, Co-Founder and President of Insilico Medicine, has been invited to attend the AIM Congress 2026 in Dubai from September 7 to 9. On September 7 (16:55–17:30), he will participate in "The Future Investment Circle" panel discussion and deliver a talk titled "The Longevity Thesis: Investing in the human lifespan". On September 8 (15:50–16:05), he will take part in a Special Spotlight Fireside session titled "AI for Science: Building the Next Trillion-Dollar Innovation Economy".
As a pioneer in AI-driven drug discovery and life sciences, Dr. Alex Aliper will represent Insilico Medicine to share deep insights with the global investment and industrial communities at the intersection of life sciences and AI. Additionally, leveraging Insilico’s latest pipeline progress and strategic roadmap, he will engage with global capital and industry partners to explore the investment value and commercialization pathways of AI-driven biopharmaceutical innovations in today's market landscape.
About AIM Congress 2026
The AIM Congress (Annual Investment Meeting) is one of the world's leading international investment promotion platforms, annually gathering thousands of representatives including heads of state, sovereign wealth funds, multinational corporations, innovative enterprises, and investment institutions. Center stage to core topics such as global investment trends, industrial transformation, the innovation economy, and sustainable development, the congress bridges multinational capital with cutting-edge industries through keynote speeches, panel discussions, country pavilions, and project matching—serving as a vital barometer for global capital flows and emerging industry opportunities.
September 8 | Macau, China
Dr. Feng Ren, Co-CEO and Chief Scientific Officer of Insilico Medicine, has been invited to attend and speak at the Fortune Leaders Forum in Macao on September 8. As an innovative practitioner in AI drug discovery, Dr. Ren will articulate how Insilico leverages artificial intelligence to revolutionize traditional drug development paradigms—accelerating breakthrough therapies from the lab to the clinic with greater efficiency and reduced costs. He will also share how AI-driven biopharmaceutical innovation unleashes long-term value across Greater China and global capital markets, grounded in Insilico’s strategic footprint in the Guangdong-Hong Kong-Macao Greater Bay Area and globally.
About the Fortune Leaders Forum
The Fortune Leaders Forum convenes top corporate executives, investors, and policymakers worldwide for high-level dialogues on business innovation, industrial transformation, and global economic trends. Featuring keynote addresses, panel discussions, and closed-door exchanges, the forum serves as a platform for cross-industry and cross-regional business leaders to exchange ideas and co-create opportunities, continuously tracking how technological innovation and capital forces reshape the global industrial landscape.
September 8–10 | Paris
Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, has been invited to speak at the Nature conference: Redefining Healthcare in the Age of AI in Paris on September 8 at 16:30. He will deliver a presentation titled "Six Aging Clocks Confirmed Biological Age Reversal in Phase IIa Trial of a Novel Therapeutic Discovered Using Aging Research and Generative AI". As a trailblazer in AI drug discovery and health tech, he will elaborate on this high-profile Phase IIa clinical trial, where the research team utilized generative AI and longevity science to discover novel therapeutics. He will highlight how six distinct aging clocks rigorously confirmed biological age reversal in humans for the first time—marking a groundbreaking milestone in anti-aging drug development.
About Nature Conference: Redefining Healthcare in the Age of AI
Initiated by Springer Nature’s prestigious Nature portfolio, this conference focuses on the frontier topic of "Redefining Healthcare in the Age of AI," bringing together world-leading scientists, clinical experts, industry captains, and policymakers. The conference addresses key areas including AI-driven drug discovery, precision medicine, digital health, clinical decision support, and health data governance, aiming to foster cross-disciplinary exchange and industrial collaboration to shape the future of AI-empowered healthcare systems.
September 8–11 | Oxford
Insilico Medicine has been invited to attend the 75th BSRA Annual Scientific Meeting (2026) at the University of Oxford from September 8 to 11. Insilico will host an exhibition booth showcasing its latest breakthroughs in longevity research, while its team of scientists will deliver keynote presentations.
Representing pioneers at the nexus of longevity science and artificial intelligence, the Insilico team will highlight recent advances in aging biomarkers and aging clocks. They will demonstrate how deep learning can precisely quantify biological age, identify age-related disease risks, and map intervention targets—charting a data-driven scientific pathway toward extending human healthspan and longevity.
About the 75th BSRA Annual Scientific Meeting
Founded in 1939, the British Society for Research on Ageing (BSRA) is one of the world's oldest academic organizations dedicated to advancing the biology of aging. Its annual scientific meeting brings together leading international scholars and early-career scientists to present cutting-edge research across cellular senescence, aging clocks, lifespan intervention, and age-related diseases. Hosted at the academic hub of the University of Oxford, the 2026 conference marks the 75th milestone anniversary of society and represents a flagship event in longevity science.
About Insilico Medicine
Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.
By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma. AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.
For more information, please visit www.insilico.com